%0 Journal Article
%T Cancer cell adaptation to chemotherapy
%A Federica Di Nicolantonio
%A Stuart J Mercer
%A Louise A Knight
%A Francis G Gabriel
%A Pauline A Whitehouse
%A Sanjay Sharma
%A Augusta Fernando
%A Sharon Glaysher
%A Silvana Di Palma
%A Penny Johnson
%A Shaw S Somers
%A Simon Toh
%A Bernie Higgins
%A Alan Lamont
%A Tim Gulliford
%A Jeremy Hurren
%A Constantinos Yiangou
%A Ian A Cree
%J BMC Cancer
%D 2005
%I BioMed Central
%R 10.1186/1471-2407-5-78
%X Cells derived from 47 tumors of breast, ovarian, esophageal, and colorectal origin and 16 paired esophageal biopsies were exposed to anticancer agents (cisplatin; 5-fluorouracil; epirubicin; doxorubicin; paclitaxel; irinotecan and topotecan) in short-term cell culture (6 days). Real-time quantitative PCR was used to measure up- or down-regulation of 16 different resistance/target genes, and when tissue was available, immunohistochemistry was used to assess the protein levels.In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp. Following exposure to doxorubicin in vitro, 13/14 breast carcinomas and 9/12 ovarian carcinomas showed >2-fold down-regulation of topoisomerase II¦Á (TOPOII¦Á). Exposure to topotecan in vitro, resulted in >4-fold down-regulation of TOPOII¦Á in 6/7 colorectal tumors and 8/10 ovarian tumors.This study suggests that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material. The molecular processes used by each tumor appear to be linked to the drug used, but there is also heterogeneity between individual tumors, even those with the same histological type, in the pattern and magnitude of response to the same drugs. Adaptation to chemotherapy may explain why prediction of resistance mechanisms is difficult on the basis of tumor type alone or individual markers, and suggests that more complex predictive methods are required to improve the response rates to chemotherapy.Tumor resistance to chemotherapy is a well-known clinical phenomenon that is now yielding its secrets to investigation at the molecular level in biopsy material. Studies in cell lines do not always correla
%U http://www.biomedcentral.com/1471-2407/5/78